Pds Biotechnology Corp (PDSB) Stock Price, Quote & News

Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies. The company's lead product candidate is Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T c...

Industry: Biotechnology

Sector: Healthcare

Phone: 800 208 3343

Website: www.pdsbiotech.com

Address:

303A College Road East, Princeton, United States

i81b4u Mar. 27 at 4:19 PM

$PDSB Just in case the company wants to R/S we are the other's.

1 · Reply

SaTwits Mar. 27 at 4:08 PM

$PDSB at this point, just do a reverse split dumb fks. Biotech is as much scince as it is a business.

0 · Reply

KG1816 Mar. 27 at 3:12 PM

$PDSB Monday is going to be a train wreck

2 · Reply

Eddie5150 Mar. 27 at 2:07 PM

$PDSB I’d like to report a murder.

1 · Reply

Mr_Charlie Mar. 27 at 9:48 AM

$PDSB reverse split to be announced next Monday, for sure.

1 · Reply

Ontherag Mar. 26 at 4:15 PM

$PDSB huge post on an interview that happened two weeks ago, yay!

2 · Reply

Mr_Charlie Mar. 26 at 3:18 PM

$PDSB it would be a dream if someone dares to buy it a $3 a share, what a dream....

2 · Reply

Mr_Charlie Mar. 26 at 1:50 PM

$PDSB back to normal folks.

0 · Reply

Ontherag Mar. 25 at 11:26 PM

$PDSB Frank the tank, LFG!

1 · Reply

ThatNurseDude Mar. 25 at 10:58 PM

$PDSB Frank’s choices are limited. raise at all time low or partnership/BO at unfavorable terms. we are out if time, out of cash, and no one believes in the platform. unfortunate.

1 · Reply

PDS Biotech Announces Conference Call and Webcast for 2025 Fourth Quarter and Year End Financial Results

Feb 20, 2026, 8:30 AM EST - 5 weeks ago

PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval

Jan 28, 2026, 8:45 AM EST - 2 months ago

PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI

Jan 22, 2026, 8:45 AM EST - 2 months ago

PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101

Jan 9, 2026, 8:45 AM EST - 2 months ago

PDS Biotech Announces FDA Alignment on use of Progression Free Survival (PFS) as Primary Endpoint

Dec 9, 2025, 8:00 AM EST - 3 months ago

PDS Biotech Announces New Composition of Matter Patent for PDS0101 in Japan

Dec 2, 2025, 8:30 AM EST - 4 months ago

PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration (“FDA”)

Nov 13, 2025, 7:30 AM EST - 4 months ago

PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update

Nov 11, 2025, 3:31 PM EST - 4 months ago

PDS Biotechnology Announces up to $11.1 Million Registered Direct Offering

Nov 10, 2025, 8:30 AM EST - 4 months ago

PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025

Nov 6, 2025, 8:00 AM EST - 5 months ago

PDS Biotech Announces Conference Call and Webcast for Third Quarter 2025 Financial Results

Oct 30, 2025, 8:00 AM EDT - 5 months ago

New Clinical and Translational Data on PDS Biotechnology's Novel Investigational Cancer Therapies PDS0101 and PDS01ADC to be Presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 29, 2025, 8:37 AM EDT - 5 months ago

PDS Biotech to Seek Expedited Approval Pathway for PDS0101 in HPV16-Positive Head and Neck Cancer

Sep 18, 2025, 8:45 AM EDT - 6 months ago

PDS Biotech Sets Significant Benchmark in Head and Neck Cancer by Achieving Extended Survival in Low PD-L1 Expression (CPS 1–19) Cohort in VERSATILE-002 Trial, Potentially Eliminating Need for Chemotherapy in the Population

Sep 2, 2025, 8:00 AM EDT - 7 months ago

PDS Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 25, 2025, 8:30 AM EDT - 7 months ago

PDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck Cancer

Aug 13, 2025, 7:00 AM EDT - 8 months ago

PDS Biotech Reports Second Quarter 2025 Financial Results and Provides Clinical Programs Update

Aug 6, 2025, 8:00 AM EDT - 8 months ago

PDS Biotech Announces Conference Call and Webcast for Second Quarter 2025 Financial Results

Jul 10, 2025, 8:00 AM EDT - 9 months ago

PDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results

Jun 9, 2025, 8:00 AM EDT - 10 months ago

PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCC

Jun 2, 2025, 8:00 AM EDT - 10 months ago

PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

May 22, 2025, 5:26 PM EDT - 11 months ago

PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

May 20, 2025, 8:00 AM EDT - 11 months ago

PDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company Showcase

May 14, 2025, 7:30 AM EDT - 11 months ago

PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update

May 9, 2025, 4:05 PM EDT - 11 months ago

PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 8, 2025, 8:00 AM EDT - 11 months ago

PDS Biotech Announces Additional Details on Two Preclinical Universal Influenza Presentations at IMMUNOLOGY2025™ Annual Meeting

May 7, 2025, 8:00 AM EDT - 11 months ago

PDS Biotech Announces Conference Call and Webcast for First Quarter 2025 Financial Results

Apr 23, 2025, 10:16 AM EDT - 1 year ago

PDS Biotech Announces Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 16, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Announces Preclinical Influenza Data to be Presented in Symposium at IMMUNOLOGY2025™ Annual Meeting

Apr 8, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Announces PDS01ADC Clinical Data to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

Mar 27, 2025, 7:30 AM EDT - 1 year ago

PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update

Mar 25, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer Conference

Mar 18, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Announces Conference Call and Webcast for Full Year 2024 Financial Results

Mar 13, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer

Mar 11, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Leadership to Participate in March Conferences

Mar 7, 2025, 8:45 AM EST - 1 year ago

PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer

Feb 27, 2025, 8:00 AM EST - 1 year ago

PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Feb 26, 2025, 8:00 AM EST - 1 year ago

PDS Biotech Announces Positive Clinical Data Demonstrating Compelling Survival and Clinical Responses in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA Oncology

Feb 24, 2025, 8:00 AM EST - 1 year ago

PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research

Feb 20, 2025, 8:00 AM EST - 1 year ago

PDS Biotech to Participate at B. Riley Securities Precision Oncology & Radiopharma Conference 2025

Dec 3, 2024, 8:00 AM EST - 1 year ago

PDS Biotech to Host Key Opinion Leader Event on December 17 at 12 p.m. ET

Nov 6, 2024, 8:00 AM EST - 1 year ago

PDS Biotech to Announce Third Quarter Financial Results on November 14, 2024 at 8:30 a.m. Eastern Time

Oct 2, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation

Sep 9, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024

Sep 3, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 7, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech to Announce Second Quarter Financial Results on August 13, 2024

Aug 1, 2024, 7:45 AM EDT - 1 year ago

PDS Biotech Aligns with FDA on Phase 3 Trial in HPV16-Positive First-Line Recurrent or Metastatic Head and Neck Cancer

Jul 31, 2024, 4:01 PM EDT - 1 year ago

PDS Biotech to Host Clinical Program Update Conference Call on August 1, 2024, at 8 a.m. Eastern Time

May 15, 2024, 8:00 AM EDT - 2 years ago

PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results

May 9, 2024, 5:46 PM EDT - 2 years ago

PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer

i81b4u Mar. 27 at 4:19 PM

$PDSB Just in case the company wants to R/S we are the other's.

1 · Reply

SaTwits Mar. 27 at 4:08 PM

$PDSB at this point, just do a reverse split dumb fks. Biotech is as much scince as it is a business.

0 · Reply

KG1816 Mar. 27 at 3:12 PM

$PDSB Monday is going to be a train wreck

2 · Reply

Eddie5150 Mar. 27 at 2:07 PM

$PDSB I’d like to report a murder.

1 · Reply

Mr_Charlie Mar. 27 at 9:48 AM

$PDSB reverse split to be announced next Monday, for sure.

1 · Reply

Ontherag Mar. 26 at 4:15 PM

$PDSB huge post on an interview that happened two weeks ago, yay!

2 · Reply

Mr_Charlie Mar. 26 at 3:18 PM

$PDSB it would be a dream if someone dares to buy it a $3 a share, what a dream....

2 · Reply

Mr_Charlie Mar. 26 at 1:50 PM

$PDSB back to normal folks.

0 · Reply

Ontherag Mar. 25 at 11:26 PM

$PDSB Frank the tank, LFG!

1 · Reply

ThatNurseDude Mar. 25 at 10:58 PM

$PDSB Frank’s choices are limited. raise at all time low or partnership/BO at unfavorable terms. we are out if time, out of cash, and no one believes in the platform. unfortunate.

1 · Reply

ThatNurseDude Mar. 25 at 9:50 PM

$PDSB likely just a routine earnings call... y’all reading too much into it just based off of the day it’s taking place… Frank’s been failing consistently to execute, no sugar coating it…

1 · Reply

alphabetsop Mar. 25 at 9:30 PM

$PDSB imo capitulation deal (not the terms they were looking for 6-12 months ago) to be announced as time has eroded their leverage.

0 · Reply

alphabetsop Mar. 25 at 9:18 PM

$PDSB If Monday 8 AM call was bad (e.g., low cash, no partner), this timing would be very unusual. Not impossible given Frank but not how struggling biotechs usually choose to deliver only negative news.

0 · Reply

NeonHornet Mar. 25 at 8:52 PM

|@SqueezeSharkie is operating on a whole different level, easily ahead of 90% of traders on this platform. |If you’re not following yet, you’re missing out. It takes 2 seconds and it’s completely free...💎 $SMMT $OCC $PDSB $DXYZ 5••

0 · Reply

kingJames407 Mar. 25 at 7:38 PM

$PDSB "clinical programs update" monday morning, exicted to be here. $MRK buyout seems like a no brainer, PDDB's lead drug boosts immune response to HPV and works alongside checkpoint inhibitor.... this stregthens Keytruda, the crowned jewel over at $MRK !!! 💰🤑

1 · Reply

Whyleb111 Mar. 25 at 7:30 PM

$PDSB feels like short covering today. I hope I’m wrong.

1 · Reply

alphabetsop Mar. 25 at 7:23 PM

$PDSB exciting times folks. what company would hold a call Monday morning before open to provide bad news with a week of trading ahead.

2 · Reply

NeonHornet Mar. 25 at 6:22 PM

$ENTX $PDSB $GUTS $SHMD ^•^

0 · Reply

Eddie5150 Mar. 25 at 5:07 PM

$PDSB why are bio’s soaring today?

1 · Reply

Kosmokrat Mar. 25 at 4:51 PM

$PDSB I hope they announce some sort of partner deal, even if it is something small, like initiation of combination trials with with big pharma partners, where the partner funds a combination trial with Versamune. Such ties with big pharma usually precede deeper partnerships or even takeovers.

2 · Reply

Test2025 Mar. 25 at 1:27 PM

$PDSB Management disclosed substantial doubt about continuing as a going concern---when did pdsb management disclosed this concern?

1 · Reply

alphabetsop Mar. 25 at 11:08 AM

$PDSB $TERN just got bought by MRK

2 · Reply

Market Cap	33.24M
Revenue (ttm)	0.00
Net Income (ttm)	-37.61M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	1.26

Volume	412,597
Avg Vol	542,618
Day's Range	N/A - N/A
Shares Out	52.37M
Stochastic %K	55%
Beta	1.20
Analysts	Strong Sell
Price Target	$7.50